Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,099.00+2.92%ETH$2,419.99+5.48%GOLD$4,075.60+3.43%OIL$88.49-7.91%
Smart Investors Daily
SID Premium
CO

NASDAQ · COYA

Coya Therapeutics, Inc.

Healthcare · Biotechnology

$3.11

Down-$0.03 (-0.96%)

Updated Nov 4, 2026, 9:28 PM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
104.01M
P/E ratio
-0.02
Dividend yield
0.00%
52-week range
$3.03 – $6.21
Volume
518.46K
Avg. volume
191.64K

Price performance · COYA

COYA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

COYA closed at $3.11 after 21 trading sessions, down 35.88% for the selected period.

Last close
$3.11
Period change
-35.88%
Period low
$3.11
Period high
$4.99
Daily close
View OHLC price history
COYA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$3.26$3.405$3.03$3.11518.46K
Nov 2, 2026$3.64$3.89$3.175$3.23270.2K
Oct 30, 2026$3.96$4.085$3.5937$3.61214.74K
Oct 29, 2026$4.08$4.20$3.95$3.9870.11K
Oct 28, 2026$4.09$4.175$4.045$4.06150.84K
Oct 27, 2026$3.97$4.30$3.94$4.1255.83K
Oct 26, 2026$3.95$4.03$3.91$3.95129.57K
Oct 23, 2026$4.08$4.245$3.935$3.94188.64K
Oct 22, 2026$4.09$4.43$4.09$4.1482.99K
Oct 21, 2026$4.23$4.29$4.10$4.1495.1K
Oct 20, 2026$4.22$4.38$4.21$4.2182.91K
Oct 19, 2026$4.29$4.535$4.20$4.20106.48K
Oct 16, 2026$4.37$4.39$4.16$4.25134.19K
Oct 15, 2026$4.18$4.50$4.14$4.34236.56K
Oct 14, 2026$4.645$4.645$4.16$4.18258K
Oct 13, 2026$4.81$4.89$4.45$4.475207.77K
Oct 12, 2026$5.00$5.05$4.81$4.81102.06K
Oct 9, 2026$5.00$5.05$4.85$4.95151.83K
Oct 8, 2026$4.91$5.00$4.7001$4.99144.42K
Oct 7, 2026$4.81$5.01$4.755$4.9195.51K
Oct 6, 2026$4.86$5.03$4.74$4.8594.63K

Latest COYA news

The latest Smart Investors Daily articles mentioning COYA.

Stock researchCompany · Overview

COYA research

Overview

Company profile and research snapshot.

Company profile

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$17.00
Implied upside
—
Analysts
13
COYA recent ratings
DateFirmRatingTarget
Sep 15, 2026BTIGBuy—
Aug 24, 2026Roth CapitalBuy—
Aug 12, 2026Chardan CapitalBuy—
Jun 12, 2026Chardan CapitalBuy—
Jun 5, 2026Roth CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting

HOUSTON, October 28, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces a poster presentation at the 2026 Annual NEALS Meeting on October 28th in Clearwater, Florida. NEALS (Network of Excellence for ALS) is the world’s largest ALS research consortium, dedicated to accelerating the development of new treatments for ALS and Motor Neuron Disease (MND).

Yahoo · Oct 14, 2026

Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS

HOUSTON, October 14, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced plans to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS).

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By